INTRODUCTION

Gabapentin (GAB) is an antiepileptic drug that has shown to be an important pharmacological treatment for several pain conditions such as diabetic neuropathic pain, postherpetic neuralgia and central pain (Eisenberg et al., 2007). It is recommended as first-line treatment for neuropathic pain as well as tricyclic antidepressants, pregabalin, duloxetine, venlafaxine, carbamazepine and oxcarbazepine (Attal et al., 2010). Furthermore, placebo-controlled clinical studies report the efficacy of GAB for the treatment of menopausal hot flashes (Guttuso et al., 2003; Butt et al., 2008) and restless legs syndrome (Garcia-Borreguero et al., 2002; Lee et al., 2011; Lal et al., 2012). The indication of therapeutic drug monitoring (TDM) has been suggested for GAB in epilepsy (Neels et al., 2004; Brandt, May, 2011; Krasowski, McMillin, 2014; Landmark et al., 2015; Patsalos, Spencer, Berry, 2018; Reimers et al., 2018). However, the benefits and therapeutic ranges for TDM of GAB in other indications have been poorly investigated so far (Burns et al., 2019).

After oral administration, GAB is rapidly absorbed with maximum plasma concentrations observed around 2-3 hours. The nonlinear pharmacokinetics of GAB with variable bioavailability suggests a saturation of the active transporters during the absorption process (Stewart et al., 1993; Patsalos, Spencer, Berry, 2018). GAB does not bind to plasma proteins, is not metabolized and is eliminated mainly unchanged by renal excretion. It shows large interindividual variability in pharmacokinetics mainly due to saturable absorption and variable renal function (Patsalos, Spencer, Berry, 2018). The most frequent adverse events reported in GAB-treated patients are dizziness and somnolence, occurring in >14% of patients (Backonja et al., 1998; Rice, Maton, 2001; Serpell, 2002; Arnold et al., 2007). GAB has been recently described

Therapeutic drug monitoring of gabapentin: the applicability in patients with neuropathic pain

Priscila Akemi Yamamoto, MS1,2; Jhohann Richard de Lima Benzi, MS2; Fabíola Dach, PhD3; Natália Valadares de Moraes, PhD4*

1Department of Drugs and Pharmaceuticals, School of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara, SP, Brazil. 2School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo (USP), Ribeirão Preto, SP, Brazil. 3Department of Neurosciences and Behavioral Sciences, Ribeirão Preto Medical School, University of São Paulo (USP), Ribeirão Preto, SP, Brazil

Gabapentin is an antiepileptic drug prescribed for several neuropathic pain conditions. This study aimed to evaluate gabapentin (GAB) trough plasma concentration range and the applicability of therapeutic drug monitoring in patients with neuropathic pain. Fifty-three patients with neuropathic pain, aged 20 to 75, received gabapentin as treatment for at least 7 days. Gabapentin plasma concentration was sampled before GAB administration and quantified by liquid chromatography with a UV detector. GAB trough plasma concentration ranged between 0.40 and 11.94 µg/mL in patients with chronic neuropathic pain. No differences were observed in terms of GAB plasma concentrations between responsive and non-responsive patients. Our data suggest that the reference ranges suggested in the literature for patients with epilepsy should not be used for patients with neuropathic pain. Therapeutic drug monitoring of GAB was shown to be an important tool to assess treatment adherence.

Keywords: Gabapentin. Therapeutic drug monitoring. Neuropathic pain.

*Correspondence: N. V. de Moraes. Departamento de Fármacos e Medicamentos. Faculdade de Ciências Farmacêuticas. Universidade Estadual Paulista “Júlio de Mesquita Filho” (UNESP). Rodovia Araraquara-Juá, km 01. Araraquara, SP, 14800-903, Brasil. Phone: +55 16 3301 4689. E-mail: natalia.v.moraes@unesp.br. ORCID: 0000-0002-4389-058X
as a drug subject to abuse, misuse and diversion (Smith, Havens, Walsh, 2016; Evoy, Morrison, Saklad, 2017).

Therefore, GAB fulfills some requirements for TDM such as large interindividual pharmacokinetic variability, compliance concerns (which hinders diagnosing therapeutic failure or correct use following a dosing regimen change) and clinically difficult to establish efficacy (Patsalos et al., 2008; Backonja, Canafax, Cundy, 2011; Krasowski, McMillin, 2014). Whereas the GAB reference range for therapeutic monitoring was proposed based on clinical studies with patients treated for epilepsy, this study aimed to evaluate trough plasma concentrations at steady state in patients with neuropathic pain.

**METHODS**

**Patients**

The clinical study was designed in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of the School of Pharmaceutical Sciences – São Paulo State University (UNESP) – with the approval of the Ethics Committee of HCFMRP-USP (ClinicalTrials.gov identifier NCT02977208). The medical charts of 124 patients with GAB prescribed as treatment for neuropathic pain, attending the Neuropathic Pain Clinic of the General Hospital of the Ribeirão Preto Medical School (HCFMRP-USP) between September 2016 and February 2018, were analyzed. All invited patients were informed of the clinical protocol and signed a free informed consent form. In summary, patients were included after receiving the same daily dose of GAB for at least 1 week to ensure that they reached the steady state of GAB plasma concentrations. In terms of neuropathic pain treatment, all patients were classified as responsive or non-responsive by an experienced neurologist. The classification was based on the patient’s declaration of pain relief improvement since the last visit. There were no restrictions on gender, weight, or race. Patients were excluded if they were pregnant or breastfeeding, using OCT2 and OCTN1 inhibitors, declared non-compliance to GAB therapy or if they declined to participate.

Blood samples were collected at steady state immediately before the dose of GAB (trough concentration) and plasma samples were stored frozen at -70 °C until analysis. Medical charts were reviewed to obtain demographic (gender, age, weight, height) and clinical data (daily dose, dose regimen, creatinine serum concentration, comorbidities, concomitant medication).

**Gabapentin plasma concentration analysis**

Samples of 100 µL of plasma were spiked with 25 µL of internal standard solution (amlodipine, 200 µg/mL). For protein precipitation, 200 µL of acetonitrile were added. A total of 200 µL of organic phase were removed to a clean tube and 200 µL 0.25 M borate buffer (pH 8.2), 30 µL 0.06 M FDNB and 1 mL acetonitrile were added. The mixture was inverted and kept in a dryer block at 65 °C for 10 min for derivatization reaction. The samples were kept at room temperature and a 25 µL 1 M HCl solution was added. After evaporated to dryness, the residues were reconstituted in 200 µL of mobile phase and 50 µL were injected into the chromatographic system.

The plasma concentration of gabapentin was analyzed by liquid chromatography with a UV detector using a reversed-phase LiChrospher® C18 RP column (125 × 4 mm, 5 µm; Merck, Darmstadt, Germany) with LiChroCART® 4-4 Purospher® RP-18 endcapped guard column (5 µm; Merck, Darmstadt, Germany). The mobile phase consisted of a mixture of 50 mM sodium phosphate buffer (pH 3.9):methanol (27:73, v/v), at a flow rate of 1.2 mL/min. Detection was performed at a wavelength of 360 nm. The method was validated following the European Medicines Agency “Guideline on Bioanalytical Method Validation” and presented linearity at the range of 0.2 to 14 µg/mL (European Medicines Agency, 2011).

**Statistical analysis**

Statistical analyses were performed using GraphPad Prism (version 6.0c for Macintosh, GraphPad Software, San Diego, CA, USA). The Mann-Whitney test was performed to compare the median values of GAB plasma concentration between responsive/non-responsive
patients. The statistical significance was set at 5% (P-value <0.05).

RESULTS

One hundred and twenty-four medical charts of patients with GAB prescription information were analyzed. However, 71 patients did not fit the inclusion criteria or could not be contacted (Figure 1). Therefore, the study was performed with 53 patients aged 20 to 75 years. The average GAB dose in the studied samples was $1553\pm804$ mg daily and ranged from 600 to 3600 mg. Table I shows the clinical indication of GAB and the most common comorbidities in the investigated patients. Antidepressants (e.g., amitriptyline, sertraline, fluoxetine), analgesics (e.g., dipyrone, codeine, paracetamol) and antihypertensives (e.g., hydrochlorothiazide, losartan, enalapril) were the most frequent drugs prescribed concomitantly with GAB.

![Flowchart](image)

**FIGURE 1** - Flowchart of enrollment and follow-up for therapeutic drug monitoring of gabapentin (GAB). Medical charts of patients with neuropathic pain were analyzed for recruitment (n=124, gray box). GAB plasma concentrations of included patients were determined (n=53, blue box). SUS: Brazil’s Unified Health System; OCT2: organic cation transporter 2; OCTN1: novel organic cation transporter 1; LOQ: limit of quantification. *Reference range: 2-20 µg/mL of GAB.
Table I. Demographic and clinical characteristics (n=53)

| Characteristics                  |       |
|----------------------------------|-------|
| Gender (men/women)              | 25/28 |
| Age (years)†                    | 54±13 (20-75) |
| Daily dose (mg)†                 | 1553±804 (600-3600) |
| Body weight (kg)†                | 78.3±14.3 (51.5-118.6) |
| BMI (kg/m²)†                     | 28.47±5.59 (20.12-44.89) |

| Indication                                      | n (%) |
|-----------------------------------------------|-------|
| Lumbar/cervical disc herniation                | 19 (35.85) |
| Central pain                                   | 7 (13.21) |
| Traumatic/postsurgical nerve injury pain       | 5 (9.43) |
| Complex regional pain syndrome                 | 4 (7.55) |
| Trigeminal neuralgia                           | 3 (5.66) |
| Diabetic neuropathic pain                      | 2 (3.77) |
| Others chronic pain                            | 13 (24.53) |

| Comorbidities                                    | n (%) |
|-----------------------------------------------|-------|
| Hypertension                                   | 27 (50.9 %) |
| Dyslipidemia                                   | 20 (37.7 %) |
| Diabetes mellitus                              | 9 (17.0 %) |

| Co-medication                                    | n (%) |
|-----------------------------------------------|-------|
| Antidepressants                                 | 34 (64.2 %) |
| Antihypertensives                               | 29 (54.7 %) |
| Analgesics                                      | 24 (45.3 %) |
| Antiulcer                                       | 19 (35.8 %) |
| Antihyperlipidemic                              | 19 (35.8 %) |
| Anticonvulsants                                 | 19 (35.8 %) |

Data are expressed as mean ± standard deviation (range). BMI: body mass index.

All patients included in this study declared to use GAB every day as prescribed, but GAB was below the lower limit of quantification in the plasma samples of three patients. These patients were invited for a second sampling and new samples were collected. In the second sampling, GAB was detected in only one patient indicating that the two other patients were not using GAB correctly. GAB observed through plasma concentration ranged between 0.40 and 11.94 µg/mL in patients treated with 600 to 3600 mg/day. The plasma concentration/daily dose (Cp/D) ratio observed ranged between 0.00028 and 0.01410 µg/mL/mg. As GAB has non-linear pharmacokinetics due to saturable drug absorption, the steady-state plasma concentration observed did not increase proportionally with dose escalation (Figure 2).
In terms of neuropathic pain control, no difference in median GAB through plasma concentration was observed between responsive (3.48 µg/mL, n=32) and non-responsive (3.97 µg/mL, n=14) patients (P-value= 0.0503; Figure 3A). The median GAB plasma concentration did not differ between responsive patients who received GAB only (Responsive, 1.93 µg/mL, n=8) and those who received other drugs for pain relief (Responsive+, 3.62 µg/mL, n=24) (Figure 3B). There was also no difference between responsive and non-responsive patients when plasma concentration was normalized by dose with median Cp/D ratio of 0.00213 and 0.00272 µg/mL/mg, respectively (P-value= 0.1590) (Figure 3C). Within responsive patients, those treated with GAB only showed a median Cp/D ratio of 0.00243 µg/mL/mg. Meanwhile, those treated with GAB associated with other drugs presented median Cp/D ratio of 0.00206 µg/mL/mg (Figure 3D). Pain control data of five patients were not available in their medical charts.
DISCUSSION

The extensive pharmacokinetic variability of GAB is an indication for TDM. After the TDM of patients treated with GAB for epilepsy and other indications, a 22- and >100-fold pharmacokinetic variability in Cp/D ratios of GAB was observed (Landmark et al., 2015; Burns et al., 2019). Large pharmacokinetic variability was also observed in this study, with a Cp/D ratio variability of 51-fold. This variability is due to the GAB dose-dependent bioavailability and the saturation of active transport during the absorption (Stewart et al., 1993; Gidal et al., 1998). Furthermore, age/glomerular filtration rate or renal drug transporters activity can influence GAB pharmacokinetics (Boyd et al., 1999; Urban et al., 2008; Lal et al., 2010; Ahmed et al., 2017; Yamamoto et al., 2019). In this study, patients using OCT2 and OCTN1 inhibitors were excluded, since these drug transporters were reported to be involved in GAB elimination (Urban et al., 2008; Lal et al., 2010). Renal function can partially explain the pharmacokinetic variability observed. Considering the current information in the literature regarding GAB renal excretion (Lal et al., 2010; Yamamoto et al., 2019; Costa et al., 2020), there are no expected drug-drug interactions at renal level between GAB and the concomitant drugs prescribed in this study.

FIGURE 3- Gabapentin (GAB) plasma levels in patients with neuropathic pain presented as absolute plasma concentration (A and B) or plasma concentrations normalized by dose (Cp/D, C and D). GAB plasma concentration and Cp/D ratio were compared between responsive and non-responsive patients (n=46, A and C) or between responsive patients treated with GAB only (Responsive, n=8) and patients receiving associated drugs for neuropathic pain (Responsive+, n=24). Data were presented as median (middle line), 25th percentile (lower line), 75th percentile (upper line) and outliers (*). The statistical significance was set at 5% (P-value <0.05).
The reference range of gabapentin (GAB) through plasma concentrations at a steady state of 2-20 µg/mL (10-120 µmol/L) is suggested in the literature for epilepsy (Sivenius et al., 1991; Wilson et al., 1998; Gatti et al., 2003; Lindberger et al., 2003; Patsalos et al., 2008; Nonoda, Iwasaki, Ishii, 2014; Reimers et al., 2018, Burns et al., 2019). Although plasma concentrations of GAB in all patients with epilepsy considered responsive were within this range, no difference was observed between responsive and non-responsive patients in terms of plasma concentrations in both adults and children (Gatti et al., 2003; Lindberger et al., 2003).

A TDM study with 223 Norwegian patients, diagnosed with epilepsy or not, showed that 31% (n=69) had GAB concentrations below the reference range proposed for epilepsy (Burns et al., 2019). Our results showed that 24.5% (n=13) of patients with neuropathic pain present GAB plasma concentration below 2 µg/mL (Figure 2). Due to the different physiopathology of epilepsy and neuropathic pain, the reference range proposed for patients with epilepsy cannot be used for patients with neuropathic pain.

TDM could play a relevant role in optimizing GAB regimen to reach the best clinical outcome with lower daily doses. However, no significant correlations were found between GAB plasma concentrations and pain intensity in 39 patients with chronic lower back pain (Atkinson et al., 2016). Similarly, no correlations between GAB plasma concentration and treatment response were observed here (Figure 3). Gabapentin efficacy is difficult to determine in patients with pain because pain is a subjective symptom reported by the patient and due to the concomitant use of other drugs for pain control, such as amitriptyline, nortriptyline, venlafaxine, baclofen, opioids, pregabalin and carbamazepine. Furthermore, the high inter-individual variability in pain modulation mechanisms can lead to different responses (Colloca et al., 2017).

In clinical practice, some patients did not use the prescribed dose of GAB correctly. During recruitment, patients complained about: a) adverse events (somnolence, gastric intolerance, swelling) which, even if not serious, were the reason for them to stop the treatment (n=3) or not follow it correctly (n=5); b) no pain relief – almost 30% of the participants do not respond to the treatment; c) the high number of medications – 32 patients included in this study used five or more medications (polypharmacy); and d) the unavailability of GAB in the public health system (Brazil’s Unified Health System – SUS) (n=5). Abuse and misuse of gabapentinoids have been reported particularly in subjects with a history of opioid abuse or psychiatric disorders (Bastiaens, Galus, Mazur, 2016; Smith, Havens, Walsh, 2016; Evoy, Morrison, Saklad, 2017).

TDM is an important tool to verify GAB treatment compliance. Compliance with treatment was self-reported in this trial. The absence of other compliance evaluations is a limitation of this study. We detected that two patients were not using GAB by observing the plasma concentration below the limit of quantification. Since, they declared the correct use of GAB and its inefficacy, other interventions were made to relieve pain, such as the addition of other drugs and nerve blocks. The false inefficacy declared by the patients can lead to unnecessary risks for them from other procedures and more complex drugs.

Even without observable associations between drug concentration and response, the TDM of GAB has a significant clinical role in avoiding misdiagnosis of therapeutic failure of GAB, especially when patients are using high doses of GAB and no pain relief is observed. The small sample size is a limitation of this study. Only patients with prescriptions of the same amount of GAB in each dose interval were included, thus limiting the inclusion of other patients.

Therapeutic drug monitoring of GAB has proven to be an important tool to assess treatment adherence. The reference ranges suggested in the literature are for patients with epilepsy and should not be applied to patients with neuropathic pain. The dose adjustment based on GAB plasma concentration for neuropathic pain treatment cannot be supported by our results, since there are no differences in trough plasma concentration and treatment response.

**ACKNOWLEDGMENTS**

This study was supported by Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.
REFERENCES

Ahmed GF, Bathena SP, Brundage RC, Leppik IE, Conway JM, Schwartz JB, et al. Pharmacokinetics and saturable absorption of gabapentin in nursing home elderly patients. AAPS J. 2017;19(2):551-6.

Arnold LM, Goldenberg DL, Stanford SB, Lalonde JK, Sandhu HS, Keck Jr PE, et al. Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum. 2007;56(4):1336-44.

Atkinson JH, Slater MA, Capparelli EV, Patel SM, Wolfson T, Gamst A, et al. A randomized controlled trial of gabapentin for chronic low back pain with and without a radiating component. Pain. 2016;157(7):1499-507.

Attal N, Cruccu G, Baron R, Haanpää M, Hannson P, Jensen TS, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17(9):1113-e88.

Backonja M, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, Hes M, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA. 1998;280(21):1831-6.

Bastiaens L, Galus J, Mazur C. Abuse of gabapentin is associated with opioid addiction. Psychiatr Q. 2016;87(4):763-767.

Boyd RA, Turck D, Abel RB, Sedman AJ, Bockbrader HN. Effects of age and gender on single-dose pharmacokinetics of gabapentin. Epilepsia. 1999;40(6):706-10.

Brandt C, May TW. Therapeutic drug monitoring of newer antiepileptic drugs / Therapeutic drug monitoring bei neueren Antiepileptika. J Lab Med. 2011;35(3):161-169.

Burns ML, Kinge E, Stokke Opdal M, Johannessen SI, Johannessen Landmark C. Therapeutic drug monitoring of gabapentin in various indications. Acta Neurol Scand. 2019;139(5):446-454.

Guttmus Jr T, Kurlan R, McDermott MP, Kieburts K. Gabapentin’s effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol. 2003;101(2):337-45.

Krasowski MD, McMillin GA. Advances in anti-epileptic drug testing. Clin Chim Acta. 2014;436:224-36.

Gidal BE, DeCerce J, Bockbrader HN, Gonzalez J, Kruger S, Pitterle ME, et al. Gabapentin bioavailability: effect of dose and frequency of administration in adult patients with epilepsy. Epilepsy Res. 1998;31(2):91-9.

Guttuso Jr T, Kurlan R, McDermott MP, Kieburts K. Gabapentin’s effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol. 2003;101(2):337-45.

Krasowski MD, McMillin GA. Advances in anti-epileptic drug testing. Clin Chim Acta. 2014;436:224-36.

Lal R, Ellenbogen A, Chen D, Zomorodi K, Atluri H, Luo W, et al. A randomized, double-blind, placebo-controlled, dose-response study to assess the pharmacokinetics, efficacy, and safety of gabapentin enacarbil in subjects with restless legs syndrome. Clin Neuropharmacol. 2012;35(4):165-73.

Lal R, Sukbuntherng J, Luo W, Vicente V, Blumenthal R, Ho J, et al. Clinical pharmacokinetic drug interaction studies of gabapentin enacarbil, a novel transported prodrug.
Therapeutic drug monitoring of gabapentin: the applicability in patients with neuropathic pain

of gabapentin, with naproxen and cimetidine. Br J Clin Pharmacol. 2010;69(5):498-507.

Landmark CJ, Beiske G, Baftiu A, Burns ML, Johannessen SI. Experience from therapeutic drug monitoring and gender aspects of gabapentin and pregabalin in clinical practice. Seizure. 2015;28:88-91.

Lee DO, Ziman RB, Perkins AT, Poceta JS, Walters AS, Barrett RW. A randomized, double-blind, placebo-controlled study to assess the efficacy and tolerability of gabapentin enacarbil in subjects with restless legs syndrome. J Clin Sleep Med. 2011;7(3):282-92.

Lindberger M, Luhr O, Johannessen SI, Larsson S, Tomson T. Serum concentrations and effects of gabapentin and vigabatrin: observations from a dose titration study. Ther Drug Monit. 2003;25(4):457-62.

Neels HM, Sierens AC, Naelaerts K, Scharpe SL, Hatfield GM, Lambert WE. Therapeutic drug monitoring of old and newer anti-epileptic drugs. Clin Chem Lab Med. 2004;42(11):1228-55.

Nonoda Y, Iwasaki T, Ishii M. The efficacy of gabapentin in children of partial seizures and the blood levels. Brain Dev. 2014;36(3):194-202.

Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, Johannessen SI, et al. Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia. 2008;49(7):1239-76.

Patsalos PN, Spencer EP, Berry DJ. Therapeutic Drug Monitoring of Antiepileptic Drugs in Epilepsy: A 2018 Update. Ther Drug Monit. 2018;40(5):526-548.

Reimers A, Berg JA, Burns ML, Brodtkorb E, Johannessen SI, Johannessen Landmark C. Reference ranges for antiepileptic drugs revisited: a practical approach to establish national guidelines. Drug Des Devel Ther. 2018;12:271-280.

Rice AS, Maton S. Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain. 2001;94(2):215-24.

Serpell MG. Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial. Pain. 2002;99(3):557-66.

Sivenius J, Kalviainen R, Ylinen A, Riekkinen P. Double-blind study of Gabapentin in the treatment of partial seizures. Epilepsia. 1991;32(4):539-42.

Smith RV, Havens JR, Walsh SL. Gabapentin misuse, abuse and diversion: a systematic review. Addiction. 2016;111(7):1160-74.

Stewart BH, Kugler AR, Thompson PR, Bockbrader HN. A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharm Res. 1993;10(2):276-81.

Urban TJ, Brown C, Castro RA, Shah N, Mercer R, Huang Y, et al. Effects of genetic variation in the novel organic cation transporter, OCTN1, on the renal clearance of gabapentin. Clin Pharmacol Ther. 2008;83(3):416-21.

Yamamoto PA, Benzi JRL, Azeredo FJ, Dach F, Ianhez Júnior E, Zanelli CF, et al. Pharmacogenetics-based population pharmacokinetic analysis of gabapentin in patients with chronic pain: Effect of OCT2 and OCTN1 gene polymorphisms. Basic Clin Pharmacol Toxicol. 2019;124(3):266-272.

Wilson EA, Sills GJ, Forrest G, Brodie MJ. High dose gabapentin in refractory partial epilepsy: clinical observations in 50 patients. Epilepsy Res. 1998;29(2):161-6.

Received for publication on 14th January 2020
Accepted for publication on 26th October 2020